Account
Insider Insights
22.03.2023
More clarity given on the proposed changes to comb...

The German government has released information regarding the 20% discounts to combination products e...

Read more
Newsletter
15.03.2023
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
09.03.2023
Government announces new action plan for rare dise...

Hope that new action plan and collaboration with the rare diseases community will progress positive ...

Read more
Articles
07.03.2023
Are acute therapies and curative drugs more afford...

We've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...

Read more
Articles
17.02.2023
How will governments face the cost of medical mira...

Among the most expensive therapies are gene therapies that show promise to transform inherited disor...

Read more
Insider Insights
25.01.2023
Singapore’s first global drug is being devel...

In a phase 3 study, Crovalimab was found to be efficacious and well tolerated in people with paroxys...

Read more
Insider Insights
24.01.2023
Takeda ready to file for TAK-755 enzyme replacemen...

Japan’s largest drugmaker Takeda says it aims to seek marketing authorisation for its TAK-755 enzy...

Read more
Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Newsletter
02.11.2022
PMA Insights: Week 44

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Insider Insights
01.11.2022
Germany – Is digitisation the gateway to better ...

Digitisation is thought to contribute significant improvements in knowledge generation in drug devel...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.